Pain relief in laour with remifentanil and ketamine

Continous infusion of Remifentanil and Ketamine compared with continous Remifentanil for pain relief in labour

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108241952N3

Enrollment

Registered

2011-12-16

Start date

2011-01-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain relief during labour. Spontaneous vertex delivery

Interventions

Intervention 1: Intervention group: a bolus dose of remifentanil 25 mg and continous infusion of 0.06 µg/kg/min remifentanil and 0.5 mg/kg/h ketamine for 4 hours (maximum dose of ketamine 2mg/kg) via

Treatment - Drugs

Intervention group: a bolus dose of remifentanil 25 mg and continous infusion of 0.06 µg/kg/min remifentanil and 0.5 mg/kg/h ketamine for 4 hours (maximum dose of ketamine 2mg/kg) via pump. After four

Control group: a bolus dose of remifentanil 25 mg and continous infusion of 0.06 mg/kg/min remifentanil.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: nulliparous, ASA I, II, gestational age 38-42 weeks in early labour Exclusion criteria: weight less than 50 kg more than 100 kg, candidate to undergo epidural analgesia, multifetus pregnancy, pre-eclampsia, premature labour, allergy to any agent under investigation, history of alcohol or drug abuse, psychiatric disorder

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain relief during labor. Timepoint: from active labor phase (cervical dilation 4-5 cm) until labour. Method of measurement: VAS score.	—

Secondary

Measure	Time frame
Heart rate. Timepoint: every 30 minutes. Method of measurement: pulse-oximetry.;SPO2. Timepoint: every 30 minutes. Method of measurement: pulse-oximetry.;Respiratory rate. Timepoint: every 30 minutes. Method of measurement: visual monitoring.;Fetal heart rate. Timepoint: every 30 minutes. Method of measurement: surface ultrasound.;Present or absent of nausea and vomiting. Timepoint: every time is peresent. Method of measurement: visual monitoring and patient's saying.;Overall effective analgesia. Timepoint: every 30 minutes after statring analgesia. Method of measurement: VAS score.;Arterial pressure. Timepoint: every 30 minutes after statrting analgesia. Method of measurement: non-invasive arterial presssure monitoring.	—

Measure

Time frame

Heart rate. Timepoint: every 30 minutes. Method of measurement: pulse-oximetry.;SPO2. Timepoint: every 30 minutes. Method of measurement: pulse-oximetry.;Respiratory rate. Timepoint: every 30 minutes. Method of measurement: visual monitoring.;Fetal heart rate. Timepoint: every 30 minutes. Method of measurement: surface ultrasound.;Present or absent of nausea and vomiting. Timepoint: every time is peresent. Method of measurement: visual monitoring and patient's saying.;Overall effective analgesia. Timepoint: every 30 minutes after statring analgesia. Method of measurement: VAS score.;Arterial pressure. Timepoint: every 30 minutes after statrting analgesia. Method of measurement: non-invasive arterial presssure monitoring.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ashraf Moini

Tehran University of Medical Sciences

a_moini@royaninstitute.org+98 21 7788 3283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026